A RANKL⁺/CXCR4⁺ B cell population accumulates in bone marrow and causes age-related osteoporosis in mice

Abstract

RANKL induces bone loss in part by promoting degradation of TRAF3, levels of which decrease in murine and human bone during aging, but the major cellular sources of RANKL in bone marrow (BM) during aging are unknown. Here, we identify RANKL⁺CXCR4⁺ B cells (RCBs) as a novel major source of RANKL in murine bone. Their numbers are increased in BM of aged WT male mice and adult mice with TRAF3 conditionally deleted in mesenchymal progenitor cells (MPCs), associated with increased expression in BM of the chemokine, CXCL12, indicating that TRAF3 in MPCs limits RCB numbers in BM of young mice. During aging, TGFβ1-induced TRAF3 degradation in MPCs promotes NF-κB-mediated expression of CXCL12, associated with higher numbers of RCBs in BM where they induce bone resorption. In addition, RCBs from aged mice caused bone loss in young NSG mice and, in an ovariectomized mouse model, accelerated osteoclastic bone resorption coupled with TRAF3 reduction and RCB accumulation in BM. Consistent with these findings, administration of the FDA-approved CXCR4 antagonist, plerixafor, reduced RCB numbers in BM and increased bone mass in naturally aged and ovariectomized mice. Reduction of RCB numbers in BM could treat/prevent osteoporosis.

References

[1] Franceschi C, Campisi J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J. Gerontol. A Biol. Sci. Med Sci., 2014, 69: S4-S9

[2] Leonardi GC, Accardi G, Monastero R, Nicoletti F, Libra M. Ageing: from inflammation to cancer. Immun. Ageing, 2018, 15: 1

[3] Libby P. Inflammation in atherosclerosis. Arterioscler Thromb. Vasc. Biol., 2012, 32: 2045-2051

[4] Akash MSH, Rehman K, Liaqat A. Tumor necrosis factor-alpha: role in development of insulin resistance and pathogenesis of type 2 diabetes mellitus. J. Cell Biochem, 2018, 119: 105-110

[5] Giunta B, et al.. Inflammaging as a prodrome to Alzheimer’s disease. J. Neuroinflammation, 2008, 5 51

[6] Robinson WH, et al.. Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis. Nat. Rev. Rheumatol., 2016, 12: 580-592

[7] Li, J. et al. TNF receptor-associated factor 6 mediates TNFalpha-induced skeletal muscle atrophy in mice during aging. J. Bone Miner. Res.35, 1535–1548 (2020).

[8] Ginaldi L, Di Benedetto MC, De Martinis M. Osteoporosis, inflammation and ageing. Immun. Ageing, 2005, 2: 14

[9] Bliuc D, et al.. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA, 2009, 301: 513-521

[10] Xiu Y, et al.. Chloroquine reduces osteoclastogenesis in murine osteoporosis by preventing TRAF3 degradation. J. Clin. Invest., 2014, 124: 297-310

[11] Dorrington MG, Fraser IDC. NF-kappaB signaling in macrophages: dynamics, crosstalk, and signal integration. Front. Immunol., 2019, 10: 705

[12] Boyce BF, Yao Z, Xing L. Functions of nuclear factor kappaB in bone. Ann. N. Y. Acad. Sci., 2010, 1192: 367-375

[13] Sun SC. The noncanonical NF-kappaB pathway. Immunol. Rev., 2012, 246: 125-140

[14] Li J, et al.. TGFbeta-induced degradation of TRAF3 in mesenchymal progenitor cells causes age-related osteoporosis. Nat. Commun., 2019, 10 2795

[15] Nikolich-Zugich J. The twilight of immunity: emerging concepts in aging of the immune system. Nat. Immunol., 2018, 19: 10-19

[16] Pang WW, et al.. Human bone marrow hematopoietic stem cells are increased in frequency and myeloid-biased with age. Proc. Natl. Acad. Sci. USA, 2011, 108: 20012-20017

[17] Kovtonyuk LV, Fritsch K, Feng X, Manz MG, Takizawa H. Inflamm-aging of hematopoiesis, hematopoietic stem cells, and the bone marrow microenvironment. Front. Immunol., 2016, 7: 502

[18] Meednu N, et al.. Production of rankl by memory b cells: a link between b cells and bone erosion in rheumatoid arthritis. Arthritis Rheumatol., 2016, 68: 805-816

[19] Yu, W. et al. Bone marrow adipogenic lineage precursors promote osteoclastogenesis in bone remodeling and pathologic bone loss. J. Clin. Invest.131, e140214 (2021).

[20] Zhou BO, Yue R, Murphy MM, Peyer JG, Morrison SJ. Leptin-receptor-expressing mesenchymal stromal cells represent the main source of bone formed by adult bone marrow. Cell Stem Cell, 2014, 15: 154-168

[21] Chakravarti A, Raquil MA, Tessier P, Poubelle PE. Surface RANKL of Toll-like receptor 4-stimulated human neutrophils activates osteoclastic bone resorption. Blood, 2009, 114: 1633-1644

[22] Ando Y, et al.. The neutrophil-osteogenic cell axis promotes bone destruction in periodontitis. Int J. Oral. Sci., 2024, 16: 18

[23] Hu Y, et al.. RANKL from bone marrow adipose lineage cells promotes osteoclast formation and bone loss. EMBO Rep., 2021, 22 e52481

[24] Xiong J, et al.. Soluble RANKL contributes to osteoclast formation in adult mice but not ovariectomy-induced bone loss. Nat. Commun., 2018, 9 2909

[25] Naradikian MS, Hao Y, Cancro MP. Age-associated B cells: key mediators of both protective and autoreactive humoral responses. Immunol. Rev., 2016, 269: 118-129

[26] Hao Y, O’Neill P, Naradikian MS, Scholz JL, Cancro MP. A B-cell subset uniquely responsive to innate stimuli accumulates in aged mice. Blood, 2011, 118: 1294-1304

[27] Richmond A, Nf-kappa B. chemokine gene transcription and tumour growth. Nat. Rev. Immunol., 2002, 2: 664-674

[28] Sun H, et al.. Design, synthesis, and characterization of a potent, nonpeptide, cell-permeable, bivalent Smac mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAP. J. Am. Chem. Soc., 2007, 129: 15279-15294

[29] Lu J, et al.. SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP. Cancer Res., 2008, 68: 9384-9393

[30] Li J, et al.. TGFbeta1+CCR5+ neutrophil subset increases in bone marrow and causes age-related osteoporosis in male mice. Nat. Commun., 2023, 14 159

[31] Xu X, et al.. Transforming growth factor-beta in stem cells and tissue homeostasis. Bone Res., 2018, 6: 2

[32] Li JY, et al.. Ovariectomy expands murine short-term hemopoietic stem cell function through T cell expressed CD40L and Wnt10B. Blood, 2013, 122: 2346-2357

[33] Onal M, et al.. Receptor activator of nuclear factor kappaB ligand (RANKL) protein expression by B lymphocytes contributes to ovariectomy-induced bone loss. J. Biol. Chem., 2012, 287: 29851-29860

[34] Franzoso G, et al.. Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev., 1997, 11: 3482-3496

[35] Li Y, Terauchi M, Vikulina T, Roser-Page S, Weitzmann MN. B cell production of both OPG and RANKL is significantly increased in aged mice. Open Bone J., 2014, 6: 8-17

[36] Lagerquist MK, et al.. Reduction of mature B cells and immunoglobulins results in increased trabecular bone. JBMR, 2022, 6e10670

[37] Xiong J, et al.. Osteocytes, not osteoblasts or lining cells, are the main source of the RANKL required for osteoclast formation in remodeling bone. PLoS One, 2015, 10: e0138189

[38] Farr JN, et al.. Identification of senescent cells in the bone microenvironment. J. Bone Min. Res., 2016, 31: 1920-1929

[39] Busse B, et al.. Decrease in the osteocyte lacunar density accompanied by hypermineralized lacunar occlusion reveals failure and delay of remodeling in aged human bone. Aging Cell, 2010, 9: 1065-1075

[40] Eghbali-Fatourechi G, et al.. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J. Clin. Invest., 2003, 111: 1221-1230

[41] McCarron MJ, Park PW, Fooksman DR. CD138 mediates selection of mature plasma cells by regulating their survival. Blood, 2017, 129: 2749-2759

[42] Phares TW, DiSano KD, Stohlman SA, Bergmann CC. Progression from IgD+ IgM+ to isotype-switched B cells is site specific during coronavirus-induced encephalomyelitis. J. Virol., 2014, 88: 8853-8867

[43] LeBien TW, Tedder TF. B lymphocytes: how they develop and function. Blood, 2008, 112: 1570-1580

[44] Lee S, Yang JI, Lee JH, Lee HW, Kim TJ. Low-level expression of CD138 marks naturally arising anergic B cells. Immune Netw., 2022, 22 e50

[45] Kind S, et al.. Prevalence of Syndecan-1 (CD138) expression in different kinds of human tumors and normal tissues. Dis. Markers, 2019, 2019 4928315

[46] Cummings SR, et al.. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N. Engl. J. Med., 2009, 361: 756-765

[47] Mueller CG, Hess E. Emerging functions of RANKL in lymphoid tissues. Front. Immunol., 2012, 3: 261

[48] Bone HG, et al.. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J. Clin. Endocrinol. Metab., 2008, 93: 2149-2157

[49] Walsh MC, Choi Y. Biology of the RANKL-RANK-OPG System in Immunity, Bone, and Beyond. Front Immunol., 2014, 5: 511

[50] Lyu H, et al.. Comparison of denosumab and bisphosphonates in patients with osteoporosis: a meta-analysis of randomized controlled trials. J. Clin. Endocrinol. Metab., 2019, 104: 1753-1765

[51] Everts-Graber J, et al.. Risk of osteonecrosis of the jaw under denosumab compared to bisphosphonates in patients with osteoporosis. J. Bone Min. Res, 2022, 37: 340-348

[52] Neer RM, et al.. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med., 2001, 344: 1434-1441

[53] Maraka S, Kennel KA. Bisphosphonates for the prevention and treatment of osteoporosis. BMJ, 2015, 351: h3783

[54] Black DM, et al.. The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT). J. Bone Miner. Res., 2015, 30: 934-944

[55] Lei W, et al.. The IAP antagonist SM-164 eliminates triple-negative breast cancer metastasis to bone and lung in mice. Sci. Rep., 2020, 10 7004

[56] Fricker SP. Physiology and pharmacology of plerixafor. Transfus. Med. Hemother., 2013, 40: 237-245

[57] De Clercq, E. Mozobil(R) (Plerixafor, AMD3100), 10 years after its approval by the US Food and Drug Administration. Antivir. Chem. Chemother.27, 2040206619829382 (2019).

[58] Stewart DA, Smith C, MacFarland R, Calandra G. Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma. Biol. Blood Marrow Transpl., 2009, 15: 39-46

[59] Srinivasan A, et al.. Phase I study of the safety and pharmacokinetics of plerixafor in children undergoing a second allogeneic hematopoietic stem cell transplantation for relapsed or refractory leukemia. Biol. Blood Marrow Transpl., 2014, 20: 1224-1228

[60] Kalatskaya I, et al.. AMD3100 is a CXCR7 ligand with allosteric agonist properties. Mol. Pharm., 2009, 75: 1240-1247

[61] Ponte F, et al.. Cxcl12 Deletion in mesenchymal cells increases bone turnover and attenuates the loss of cortical bone caused by estrogen deficiency in mice. J. Bone Miner. Res., 2020, 35: 1441-1451

[62] Gulick RM, et al.. Maraviroc for previously treated patients with R5 HIV-1 infection. N. Engl. J. Med, 2008, 359: 1429-1441

[63] Brave M, et al.. FDA review summary: mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation. Oncology, 2010, 78: 282-288

[64] Komatsu, N. et al. Plasma cells promote osteoclastogenesis and periarticular bone loss in autoimmune arthritis. J. Clin. Invest.131, e143060 (2021).

[65] Pillay J, et al.. Effect of the CXCR4 antagonist plerixafor on endogenous neutrophil dynamics in the bone marrow, lung and spleen. J. Leukoc. Biol., 2020, 107: 1175-1185

[66] McComb S, et al.. cIAP1 and cIAP2 limit macrophage necroptosis by inhibiting Rip1 and Rip3 activation. Cell Death Differ., 2012, 19: 1791-1801

[67] Li J, et al.. BMI-1 mediates estrogen-deficiency-induced bone loss by inhibiting reactive oxygen species accumulation and T cell activation. J. Bone Miner. Res., 2017, 32: 962-973

[68] Yao Z, et al.. NF-kappaB RelB negatively regulates osteoblast differentiation and bone formation. J. Bone Miner. Res., 2014, 29: 866-877

Funding

U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)(R01AR43510)

U.S. Department of Health & Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging)(R01AG049994)

National Natural Science Foundation of China (National Science Foundation of China)(82472481)

RIGHTS & PERMISSIONS

The Author(s)